04 octubre 2012

Nypta en Fase II Alzheimer . Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients (ARGO) : This Study Has Been Completed. .

Enrollment: 306


Study Start Date: April 2011

Study Completion Date: October 2012

Primary Completion Date: July 2012 (Final data collection date for primary outcome measure) .

Status Completed .

************************************

Administrative Data


Organization name Noscira SA

Organization study ID NP031112-10B04

Sponsor Noscira SA

Collaborator ICON Clinical Research

Health Authority Spain: Agencia Española de Medicamentos y Productos Sanitarios

Health Authority France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Health Authority United Kingdom: Medicines and Healthcare Products Regulatory Agency

Health Authority Germany: Federal Institute for Drugs and Medical Devices

Health Authority Belgium: Federal Agency for Medicinal Products and Health Products

Health Authority Finland: Finnish Medicines Agency